Is a complete HAE research report available?

No complete published report is available for Haemonetics Corporation (HAE) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

HAE Stock Analysis, Forecast & Valuation

Market cap	3.9B
Revenue (ttm)	1.3B
Net income (ttm)	97.3M
EPS (ttm)	$2.05
Shares out	45.4M
P/E (trailing)	41.7x
P/E (forward)	16.4x
Volume	893,443
Beta	0.52

Price target	$87.9	+2.9%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	38.3B	72.6x	8.9x	78.4%	+49.7%	-11.8%	Strong Buy
ARGX	argenx SE	55.2B	32.2x	10.4x	50.6%	+58.8%	+48.3%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All HAE indicators

Market & fundamental data

Available fields

272

Groups with data

Currency

USD

Showing 272 of 272 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0000313143
Company name	Haemonetics Corporation
Country	United States
Country code	US
Cusip	405024100
Employees	3,009
Employees Change	-14%
Employees Change Percent	-0.46
Enterprise value	$4.9B
Exchange	NYSE
Financial currency	USD
First seen	2026-05-09
Industry	Medical Devices
Industry PE	41.91
Industry PE Fwd	19.62
IPO Date	1991-05-09
Isin	US4050241003
Last refreshed	2026-07-30
Market cap	$3.9B
Market cap category	Mid-Cap
Price	$85.42
Price currency	USD
Rev Per Employee	443,345.63x
Sector	Healthcare
Sector PE	45.6
Sector PE Fwd	24.3
Sic	3841
Symbol	HAE
Website	https://www.haemonetics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	2.51%
EV Earnings	50.46x
EV Sales Forward	3.5x
EV/EBIT	31.33x
EV/EBITDA	18.29x
EV/FCF	18.85x
EV/Sales	3.68x
FCF yield	6.71%
Forward P/E	16.37x
P/B ratio	4.85x
P/E ratio	41.67x
P/S ratio	2.91x
PE Ratio10 Y	93.23x
PE Ratio3 Y	28.28x
PE Ratio5 Y	43.89x
PEG ratio	1.51x
PS Forward	2.77x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	11.75%
EBITDA Margin	20.12%
FCF margin	19.52%
Gross margin	59.43%
Gross Profit	$792.9M
Gross Profit Growth	1.84%
Gross Profit Growth Q	-0.45%
Gross Profit Growth3 Y	8.38%
Gross Profit Growth5 Y	13.1%
Net Income	$97.3M
Net Income Growth	-41.97%
Net Income Growth Years	0%
Net Income Growth3 Y	-5.53%
Net Income Growth5 Y	4.13%
Pretax Margin	9.6%
Profit Margin	7.29%
Profit Per Employee	$32,339
Profitable Years	9
ROA	6.49
Roa5y	5.69
ROCE	7.42
ROE	12.03
Roe5y	12.93
ROIC	10.63
Roic5y	9.59

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	11.09%
Cagr15y	6.63%
Cagr1y	14.42%
Cagr20y	7.29%
Cagr3y	-2.8%
Cagr5y	7.47%
EPS Growth	-38.07
EPS Growth Years	0
EPS Growth3 Y	-2.91
EPS Growth5 Y	5.75
FCF Growth	82.83%
FCF Growth Q	-47.2%
FCF Growth3 Y	47.15%
FCF Growth5 Y	29.41%
OCF Growth	61.35%
OCF Growth Q	-39.14%
OCF Growth10 Y	9.18%
OCF Growth3 Y	2.4%
OCF Growth5 Y	21.93%
Revenue Growth	-1.97x
Revenue Growth Q	4.77x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	4.51x
Revenue Growth5 Y	8.91x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.55
Assets	$2.4B
Cash	$246.3M
Current Assets	$834.9M
Current Liabilities	$282.6M
Debt	$1.3B
Debt EBITDA	$4.75
Debt Equity	$1.6
Debt FCF	$4.89
Equity	$796.3M
Interest Coverage	8.12
Liabilities	$1.6B
Long Term Assets	$1.6B
Long Term Liabilities	$1.3B
Net Cash	$-1B
Net Cash By Market Cap	$-26.49
Net Debt EBITDA	$3.83
Net Debt Equity	$1.29
Net Debt FCF	$3.95
Tangible Book Value	$-370.1M
Tangible Book Value Per Share	$-8.18
WACC	5.64

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.95
Inventory Turnover	1.61
Net Working Capital	$320.3M
Quick ratio	1.64
Working Capital	$552.3M
Working Capital Turnover	$2.93

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	6.65%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	186.26%
1Y total return	14.41%
200-day SMA	67.28
3Y total return	-8.18%
50-day SMA	73.4
50-day SMA vs 200-day SMA	50over200
5Y total return	43.35%
All Time High	142.1
All Time High Change	-39.89%
All Time High Date	2021-02-09
All Time Low	5.78
All Time Low Change	1,377.6%
All Time Low Date	1991-05-10
ATR	2.71
Beta	0.52
Beta1y	-0.31
Beta2y	0.48
Ch YTD	6.58
High	85.71
High52	87.32
High52 Date	2025-12-10
High52ch	-2.18%
Low	81.72
Low52	47.32
Low52 Date	2025-09-26
Low52ch	80.54%
Ma50ch	16.38%
Premarket Change Percent	-1.26
Premarket Price	$81.5
Premarket Volume	472
Price vs 200-day SMA	26.97%
RSI	75.48
RSI Monthly	57.28
RSI Weekly	69.24
Sharpe ratio	0.44x
Sortino ratio	0.79
Total Return	6.65%
Tr YTD	6.58
Tr15y	162.11%
Tr1m	10.52%
Tr1w	9.47%
Tr3m	42.75%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	11
Analyst Count Top	2
Analyst Price Target Top	$90
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$1.09
Earnings EPS Estimate Growth	-0.91
Earnings Revenue Estimate	329,189,064x
Earnings Revenue Estimate Growth	2.43x
Operating Income	$251.5M
Operating Income Growth	1.79
Operating Income Growth Q	-13.44
Operating Income Growth3 Y	14.58
Operating Income Growth5 Y	20.24
Operating margin	18.86
Price target	$87.9
Price Target Change	$2.9
Price Target Change Top	$5.36

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	44,855,725%
Float Percent	98.7%
Net Borrowing	-6,250,000
Shares Insiders	1.3%
Shares Institutions	98.35%
Shares Out	45,445,983
Shares Qo Q	-1.62%
Shares Yo Y	-6.66%
Short Float	6.02%
Short Ratio	3.42
Short Shares	5.94

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$226.6M
Adjusted OCF	259,394,000
Average Volume	633,165.75x
Bv Per Share	17.6
CAPEX	$-32.8M
Ch10y	186.3
Ch15y	162.1
Ch1m	10.52
Ch1w	9.47
Ch1y	14.41
Ch20y	308.2
Ch3m	42.75
Ch3y	-8.18
Ch5y	43.35
Ch6m	29.31
Change	3.49%
Change From Open	4.18
Close	82.54
Days Gap	-0.67
Depreciation Amortization	105,617,000
Dollar Volume	76,317,901.1
Earnings Date	2026-08-06
Earnings Time	bmo
EBIT	$156.7M
EBITDA	$268.5M
EPS	$2.05
F Score	6
FCF	$260.4M
FCF EV Yield	5.3x
FCF Per Share	$5.73
Financing CF	-178,460,000
Fiscal Year End	March
Founded	1,971
Goodwill	656,368,000
Graham Number	28.48983
Graham Upside	-66.65
Income Tax	$30.7M
Investing CF	-179,547,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-28
Last Split Date	2012-12-03
Last Split Type	Forward
Last10k Filing Date	2026-05-20
Lynch Fair Value	$10.25
Lynch Upside	-88
Ma150	67.11
Ma150ch	27.29%
Ma20	77.37
Ma20ch	10.4%
Net CF	-61,323,000
Next Earnings Date	2026-08-06
Open	81.99
Optionable	Yes
P FCF Ratio	14.91
P FCF Ratio SBC	17.13
P OCF Ratio	13.24
P OCF Ratio SBC	14.97
Position In Range	92.73
Ppne	345,380,000
Pre Close	82.54
Price Date	2026-07-29
Price EBITDA	$14.46
Relative Volume	1.41x
Revenue	1,334,027,000x
SBC By Revenue	2.54x
Share Based Comp	33,827,000
Tax By Revenue	2.3x
Tax Rate	24%
Tr20y	308.22%
Tr6m	29.31%
Us State	Massachusetts
Volume	893,443
Z Score	2.51

Haemonetics Corporation (HAE)

Coverage state: Market snapshot only — no published research

Generate the first HAE analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · HAE

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All HAE indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on HAE

Frequently asked questions